Shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) have earned an average rating of “Buy” from the nine ratings firms that are currently covering the stock, MarketBeat.com reports. One research analyst has rated the stock with a sell recommendation, two have given a hold recommendation and six have given a buy recommendation to the company. The average 12-month price target among brokers that have issued a report on the stock in the last year is $248.00.

A number of research analysts recently issued reports on the company. Credit Suisse Group boosted their price target on IDEXX Laboratories from $255.00 to $259.00 and gave the company an “outperform” rating in a report on Friday, August 17th. BidaskClub downgraded IDEXX Laboratories from a “strong-buy” rating to a “buy” rating in a report on Tuesday, September 11th. Bank of America reduced their price target on IDEXX Laboratories from $275.00 to $235.00 and set a “buy” rating on the stock in a report on Friday, November 2nd. Finally, Canaccord Genuity reduced their price target on IDEXX Laboratories from $270.00 to $250.00 and set a “buy” rating on the stock in a report on Monday, November 5th.

In other IDEXX Laboratories news, VP Jacqueline Studer sold 3,313 shares of the company’s stock in a transaction that occurred on Tuesday, November 6th. The stock was sold at an average price of $201.27, for a total transaction of $666,807.51. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director Rebecca M. Henderson sold 3,504 shares of the company’s stock in a transaction that occurred on Tuesday, November 27th. The stock was sold at an average price of $194.92, for a total value of $682,999.68. Following the transaction, the director now owns 22,200 shares in the company, valued at approximately $4,327,224. The disclosure for this sale can be found here. 2.56% of the stock is owned by insiders.

Several hedge funds have recently bought and sold shares of IDXX. Marshall Wace North America L.P. boosted its position in shares of IDEXX Laboratories by 166.9% in the 3rd quarter. Marshall Wace North America L.P. now owns 55,012 shares of the company’s stock worth $13,734,000 after purchasing an additional 34,404 shares in the last quarter. Great Lakes Advisors LLC boosted its position in shares of IDEXX Laboratories by 1.0% in the 3rd quarter. Great Lakes Advisors LLC now owns 13,766 shares of the company’s stock worth $3,437,000 after purchasing an additional 142 shares in the last quarter. Vanguard Group Inc. boosted its position in shares of IDEXX Laboratories by 0.3% in the 3rd quarter. Vanguard Group Inc. now owns 8,918,451 shares of the company’s stock worth $2,226,581,000 after purchasing an additional 23,970 shares in the last quarter. Morgan Stanley boosted its position in shares of IDEXX Laboratories by 15.1% in the 3rd quarter. Morgan Stanley now owns 439,913 shares of the company’s stock worth $109,830,000 after purchasing an additional 57,828 shares in the last quarter. Finally, Kepos Capital LP boosted its position in shares of IDEXX Laboratories by 5.0% in the 3rd quarter. Kepos Capital LP now owns 17,808 shares of the company’s stock worth $4,446,000 after purchasing an additional 851 shares in the last quarter. Hedge funds and other institutional investors own 91.14% of the company’s stock.

Shares of NASDAQ IDXX traded down $7.20 during midday trading on Friday, reaching $192.49. The company had a trading volume of 4,906 shares, compared to its average volume of 431,501. IDEXX Laboratories has a one year low of $154.88 and a one year high of $256.22. The firm has a market cap of $16.97 billion, a PE ratio of 59.00, a price-to-earnings-growth ratio of 2.50 and a beta of 0.84.

IDEXX Laboratories (NASDAQ:IDXX) last released its earnings results on Thursday, November 1st. The company reported $1.05 earnings per share for the quarter, beating analysts’ consensus estimates of $0.97 by $0.08. IDEXX Laboratories had a negative return on equity of 994.76% and a net margin of 15.19%. The company had revenue of $545.00 million during the quarter, compared to analyst estimates of $545.66 million. During the same quarter in the previous year, the company posted $0.76 EPS. IDEXX Laboratories’s revenue for the quarter was up 10.8% on a year-over-year basis. On average, sell-side analysts anticipate that IDEXX Laboratories will post 4.19 earnings per share for the current year.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc, together with its subsidiaries, develops, manufactures, and distributes products and services primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets worldwide. It operates through Companion Animal Group; Water Quality Products; Livestock, Poultry and Dairy; and Other segments.

Featured Article: Municipal Bonds

Analyst Recommendations for IDEXX Laboratories (NASDAQ:IDXX)

Receive News & Ratings for IDEXX Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IDEXX Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.